Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 3.
Figure 3.

Human SOST dose effect on bone metabolism in the proximal tibia metaphysis of 5-mo-old male mice (non-tg = 5; SOSTwt = 7; SOSTwt/wt = 4). (A) Bone volume and (B) bone formation rates as determined by microCT scans and histomorphometric analysis, respectively. Mean ± SEM; (*) p < 0.05 vs. non-tg; (X) p < 0.05 vs. SOSTwt. (C) Cancellous bone compartment of nontransgenic and SOSTwt/wt mice. (D) Fluorochrome marker uptake at site of active mineralization of bone matrix laid down by osteoblasts in wild-type and transgenic mice at the interface between endocortex and cancellous bone.

This Article

  1. Genome Res. 15: 928-935

Preprint Server